About this Series

Nonalcoholic steatohepatitis (NASH), the progressive and destructive form of nonalcoholic fatty liver disease, is not well known but is about to overtake hepatitis C as the leading cause of liver transplantation in the United States. The National Institutes of Health estimates that as many as 12% of US adults—30 million people—have NASH. Most individuals are not aware that they have the disease until significant liver damage has already occurred. The consequences of NASH can include ascites, bleeding varices of the esophagus, cirrhosis, and hepatocellular carcinoma.

Currently, there are no FDA-approved therapies for the treatment of NASH, but earlier diagnosis and lifestyle changes such as weight loss and exercise have been shown to reduce the risk for disease progression and in some cases may reverse disease severity.

In this series, hepatology experts discuss the critical need for greater awareness of NASH (and its key risk factors) among healthcare providers. The specialists also share management strategies to help slow disease progression and discuss potential new therapies in clinical development.

Show More

Who's Who
More on Nonalcoholic Steatohepatitis